Jazz Pharmaceuticals PLC (JAZZ) saw its stock price plummet 6.16% in Tuesday's trading session following the release of its first-quarter 2025 financial results, which significantly missed analyst expectations across key metrics.
The biopharmaceutical company reported Q1 revenue of $897.841 million, falling short of the IBES estimate of $985.4 million. Adjusted earnings per share (EPS) came in at $1.68, well below the expected $4.66. The company's adjusted net income for the quarter was $105.233 million, considerably lower than the estimated $288.6 million. Jazz Pharmaceuticals also reported a net loss of $92.541 million, translating to a loss per share of $1.52.
In light of these disappointing results, Jazz Pharmaceuticals announced updates to its 2025 financial guidance, though specific details were not immediately available. Investors and analysts will likely be closely monitoring the company's future outlook and potential strategies to improve performance in the coming quarters.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。